Analysts’ Perspective: Intellia Therapeutics (NTLA), Gap (GPS), Ternium S.A. (TX)

Investment Analysts at Chardan Capital Markets upgraded Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares from Neutral to Buy rating while increasing their price target from $20 to $57.50.

Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system..

*

Brokerage Firm Telsey Advisory Group upgraded The Gap, Inc. (NYSE:GPS) shares from Market Perform to Outperform rating with a price target of $39.

The Gap, Inc. operates as an apparel retail company worldwide.

*

Ternium S.A. (NYSE:TX) shares were upgraded by analysts at Credit Suisse from Neutral to Outperform rating.

Ternium S.A., through its subsidiaries, manufactures and processes various steel products in Mexico, Argentina, Paraguay, Chile, Bolivia, Uruguay, Brazil, the United States, Colombia, Guatemala, Costa Rica, Honduras, El Salvador, and Nicaragua.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/